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ttp://dx.doi.org/10.1016/j.ajpath.2014.01.021Lymphatics proliferate, become enlarged, or regress in multiple inﬂammatory lung diseases in humans.
Lymphatic growth and remodeling is known to occur in the mouse trachea in sustained inﬂammation, but
whether intrapulmonary lymphatics exhibit similar plasticity is unknown. We examined the time course,
distribution, and dependence on vascular endothelial growth factor receptor (VEGFR)-2/VEGFR-3
signaling of lung lymphatics in sustained inﬂammation. Lymphatics in mouse lungs were examined under
baseline conditions and 3 to 28 days after Mycoplasma pulmonis infection, using prospero heomeobox 1e
enhanced green ﬂuorescence protein and VEGFR-3 as markers. Sprouting lymphangiogenesis was evident
at 7 days. Lymphatic growth was restricted to regions of bronchus-associated lymphoid tissue (BALT),
where VEGF-Ceproducing cells were scattered in T-cell zones. Expansion of lung lymphatics after infection
was reduced 68% by blocking VEGFR-2, 83% by blocking VEGFR-3, and 99% by blocking both receptors.
Inhibition of VEGFR-2/VEGFR-3 did not prevent the formation of BALT. Treatment of established infection
with oxytetracycline caused BALT, but not the lymphatics, to regress. We conclude that robust lym-
phangiogenesis occurs in mouse lungs afterM. pulmonis infection through a mechanism involving signaling
of both VEGFR-2 and VEGFR-3. Expansion of the lymphatic network is restricted to regions of BALT, but
lymphatics do not regress when BALT regresses after antibiotic treatment. The lung lymphatic network can
thus expand in sustained inﬂammation, but the expansion is not as reversible as the accompanying
inﬂammation. (Am J Pathol 2014, 184: 1577e1592; http://dx.doi.org/10.1016/j.ajpath.2014.01.021)This work was supported in part by funding from grants HL024136 and
HL59157 from National Heart, Lung, and Blood Institute of the U.S. Na-
tional Institutes of Health, AngelWorks, and from the Leducq Foundation
(D.M.M.).
Disclosures: None declared.Lymphatic vessels undergo changes in many inﬂammatory
lung diseases, where lymphatic proliferation, enlargement, and
regression have been described.1,2 Examples include asthma,
where lymphatics regress,3 chronic obstructive pulmonary
disease (COPD) and pneumonia, where they proliferate,4e6
and idiopathic pulmonary ﬁbrosis, where they undergo
abnormal growth and remodeling in the lung parenchyma7,8
but regress in subpleural and interlobular compartments.9
Although lymphatics are well known to drain interstitial
ﬂuid and serve as conduits for antigen-presenting cells and
lymphocytes from the lung,10e12 little has been learned about
the mechanism and functional implications of lymphatic
changes in pulmonary inﬂammation. Regardless of the
impact of lymphangiogenesis on disease pathophysiological
characteristics, the presence of edema in inﬂammatory lung
disease indicates that the amount of plasma leakage exceedsstigative Pathology.
.the ﬂuid drainage capacity through lymphatics and other
routes.
Lymphatics proliferate in many settings of sustained
inﬂammation, including psoriasis,13 rheumatoid arthritis,14
and inﬂammatory bowel disease,15 but it is still unclear
whether proliferation of lymphatics worsens or amelio-
rates disease severity. Promotion of lymphatic growth by
transgenic overexpression of vascular endothelial growth
factor (VEGF)-C reduces the severity of skin inﬂamma-
tion.16 This effect has not been examined in the lung, and
Baluk et alit is unknown whether it is typical of inﬂammatory con-
ditions in other organs. It is also unclear whether lung
lymphatics exhibit the same plasticity in inﬂammation as
those in other organs.
Previous studies had shown that tracheal lymphatics un-
dergo widespread growth and remodeling after infection.
During the ﬁrst 4 weeks after infection, tracheal lymphatics
undergo even more extensive changes than blood ves-
sels.17,18 However, sensitization and challenge of lungs to
house dust mite allergen for 2 weeks has no detectable effect
on the number of lung lymphatics.19 Little is known about
the effects on lung lymphatics of other conditions of sus-
tained inﬂammation.
We, therefore, used a mouse model of sustained lung
inﬂammation produced by respiratory tract infection by
Mycoplasma pulmonis bacteria to determine the response of
lung lymphatics to sustained inﬂammation and to compare
changes in the lung with those in the trachea. With the pre-
sumption that lymphangiogenesis does occur in the lung, we
sought to determine exactly when and where. During the
period of 1 to 4 weeks after infection, we closely observed the
distribution of the changes in the lung to address the possi-
bility that lymphatic growth or remodeling was regionally
speciﬁc.
We also investigated the driving mechanism for lymphatic
growth in lungs in this model. Because of compelling evi-
dence that lymphatic growth in the trachea and other settings
is driven by VEGF-C activation of VEGF receptor
(VEGFR)-3 signaling,20 we compared the effects in the lung
and trachea of blocking VEGFR-2 and VEGFR-3 adminis-
tered individually or together.
Consistent with this reasoning, previous studies revealed
that lymphangiogenesis in the trachea after M. pulmonis
infection was completely inhibited by a function-blocking
antibody to VEGFR-3.17 Similar results have been obtained
in skin21 and cornea.22 However, lymphangiogenesis under
some conditions is also partially reduced by selective inhi-
bition of VEGFR-2, examples being skin,23 cornea,24 lymph
nodes,25 arthritic joints,24 and tumors.26 The latter mecha-
nism could reﬂect effects of VEGFR-2 blockade directly on
lymphatics or indirectly through changes in leukocytes or
other cells that produce lymphangiogenic factors.
The present study of lymphatic remodeling in sustained
bronchopneumonia produced by M. pulmonis infection
addressed the question of whether lymphatics grow, un-
dergo remodeling, or regress during the development of
bronchopneumonia. The study also examined the time
course of changes in lymphatics, whether the distribution of
lymphangiogenesis coincides with the widespread inﬂam-
matory changes in the lung, and whether lymphatic growth
and remodeling in the lung is driven by changes in signaling
of VEGFR-3, VEGFR-2, or both.
The experiments revealed that some lymphatics in the
lung underwent profound changes after M. pulmonis infec-
tion. Sprouting lymphangiogenesis was evident at 1 week
and was more pronounced at 2 and 4 weeks. Strikingly,1578expansion of the lymphatic network was restricted to re-
gions of bronchus-associated lymphoid tissue (BALT) that
formed in the lung around bronchi and major pulmonary
vessels. Lymphatics in more peripheral regions of the lung
did not exhibit these changes, despite the presence of in-
ﬂammatory cells. Growth of lymphatics in BALT was
blocked 99% by inhibition of VEGFR-2 and VEGFR-3
together. Inhibition of VEGFR-3 alone resulted in 83%
reduction, whereas inhibition of VEGFR-2 alone resulted in
68% reduction. Inhibition of lymphangiogenesis in BALT




Mice used were C57BL/6 strain, speciﬁc pathogen free, and
housed under barrier conditions. They included wild-type
mice (Charles River, Hollister, CA), prospero heomeobox 1
(Prox1)eenhanced green ﬂuorescence protein (EGFP)e
transgenic mice with ﬂuorescent green lymphatics,27 and
CC10eVEGF-Aetransgenic mice overexpressing human
VEGF-A in epithelial cells of airways and lungs.28Mice were
anesthetized by i.m. injection of 87 mg/kg ketamine and 13
mg/kg xylazine. The Institutional Animal Care and Use
Committee of the University of California, San Francisco,
approved all experimental procedures.
M. pulmonis Infection and Antibiotic Treatment
Anesthetized mice were infected with M. pulmonis by
intranasal inoculation of 25 mL per nostril of broth con-
taining a total of 106 colony-forming units of organisms
(strain CT7), as described previously.17 In some experi-
ments, mice were treated for 14 days by daily i.p. injection
of 100 mg/kg oxytetracycline (Liquamycin; Pﬁzer, Sao
Paulo, Brazil) to eliminate the infection.
Inhibition of VEGF-2 and/or VEGFR-3 Signaling
Function-blocking rat monoclonal antibodies were used to
block VEGFR-2 (clone DC101) and/or VEGFR-3 (clone
mF4-31C1) (ImClone Systems, New York, NY).17 Anti-
bodies were injected i.p. at a dose of 0.8 mg in a volume of
200 mL of 0.9% sterile NaCl solution per mouse 1 day
before infection, then every other day for 14 days. Rat IgG
(Jackson ImmunoResearch Labs Inc., West Grove, PA) was
used as a control.
Fixation and Tissue Preparation
The vasculature of anesthetized mice was perfused for 2
minutes at a pressure of 120 to 140 mmHg with ﬁxative (1%
paraformaldehyde in PBS, pH 7.4; Sigma-Aldrich, St.
Louis, MO) from a cannula inserted through the leftajp.amjpathol.org - The American Journal of Pathology
Lymphangiogenesis in Lung Inﬂammationventricle into the aorta. In some cases, the pulmonary cir-
culation was ﬁrst ﬂushed by insertion of the cannula into the
right ventricle at the origin of the pulmonary artery and
perfusion at a pressure of 20 mmHg until the lungs turned
white. To preserve alveoli in an expanded condition, lungs
were inﬂated with 0.4 mL of melted 1% SeaPlaque low-
melting point agarose (Lonza, Rockland, ME) in PBS
slowly administered intratracheally via a syringe and an 18-
gauge catheter. Tracheas, bronchial lymph nodes, and lungs
were removed, weighed, and immersed in ﬁxative for 1 hour
at 4C and then washed with PBS. The left lung was cut
transversely into three parts, such that the middle part
contained the main bronchus and the major pulmonary
blood vessels were cut in cross section approximately 3 mm
below the hilum (Figure 1). The left lung sections and whole
right lungs were embedded ﬂat in Tissue-Tek medium
(Sakura, Torrance, CA) and frozen as cryostat blocks.
IHC Data
Tissues were washed and stained immunohistochemically
(IHC) by incubating cryostat sections (200 mm thick) of the
mid left lung cut transversely or whole mounts of trachea with
one or more primary antibodies diluted in PBS containing
0.3% Triton X-100 (Sigma-Aldrich), 0.2% bovine serumFigure 1 Schematic of mouse lungs and regions used for analysis. The
midportion of the left (L.) lung was embedded ﬂat, and cryostat sections
(200 mm thick) were stained IHC and then analyzed to compute the
abundance of lymphatics by superimposing stereological counting grids on
projected microscope images of lung regions of standard size. Lungs and
bronchial lymph nodes were weighed. L, left; R, right.
The American Journal of Pathology - ajp.amjpathol.orgalbumin (Sigma-Aldrich), 10% normal serum (Jackson
ImmunoResearch Labs Inc.), and 0.1% sodium azide (Sigma-
Aldrich).17We used the following antibodies to identify blood
vessels: platelet endothelial cell adhesion molecule
(PECAM)-1 (CD31) (hamster anti-mouse monoclonal, clone
2H8, MA3105; Thermo Fisher Scientiﬁc, Rockford, IL);
lymphatics, such as VEGFR-3 (goat anti-mouse polyclonal
AF743; R&D Systems, Minneapolis, MN); lymphatic vessel
endothelial cell marker (LYVE)-1 (rabbit anti-mouse poly-
clonal 11-034; AngioBio, Del Mar, CA); podoplanin (Syrian
hamster anti-mouse monoclonal, clone 8.1.1; AngioBio);
neuropilin-2 (goat polyclonal AF567; R&D Systems); che-
mokine ligand (CCL) 21 (goat polyclonal AF457; R&D
Systems); VEGF-C (goat polyclonal sc-7132; Santa Cruz
Biotechnology, Dallas, TX); Prox1 (rabbit anti-mouse poly-
clonal AB5475; Millipore, Billerica, MA); smooth muscle
cells, such as a-smooth muscle actin (aSMA; mouse mono-
clonal, clone 1A4 conjugated to ﬂuorescein isothiocyanate,
F3777, or Cy3; C6198; Sigma-Aldrich); pan-leukocyte
marker CD45 (rat anti-mouse monoclonal, clone 30-F11;
BioLegend, SanDiego,CA);B lymphocytes, suchasB220 (rat
anti-mousemonoclonal, cloneRA3-6B2;BDBiosciences, San
Jose CA); T lymphocytes, such as CD3e (Armenian hamster
anti-mouse monoclonal, clone 145-2C11; BD Biosciences);
macrophages and dendritic cells, such as allograft inﬂamma-
tory factor 1/ionized calcium-binding protein 1 (Aif1/Iba1;
Wako USA, Richmond, VA); neutrophils, such as S100A8
(goat polyclonal AF3059; R&D Systems); high endothelial
venules (HEVs), such as MECA-79 (PNAd carbohydrate
epitope, CD62L, rat anti-mousemonoclonal, cloneMECA-79;
BD Biosciences); lung epithelial cells (primarily alveolar type
1 cells), such as aquaporin-5 (rabbit polyclonal ab78486;
Abcam,Cambridge,MA)or pan-cytokeratin (rabbit polyclonal
Z0622;DakoUSA,Carpinteria, CA); epithelialmicrofold cells
(M cells), such as biotinylated Ulex europaeus lectin B1065
(Vector Laboratories, Burlingame, CA); and endogenous
EGFP ﬂuorescence, ampliﬁed by chicken polyclonal anti-GFP
(GFP-1020; Aves Labs, Tigard, OR).
Secondary antibodies were labeled with Dy488 or
Alexa488, Cy3, or Cy5 or Dy649 (Jackson ImmunoResearch
Labs Inc.). Specimens were viewed with a Zeiss Axiophot
ﬂuorescence microscope (Zeiss USA, Thornwood, NY)
equipped with a threeecharge-coupled device low-light red,
green, blue (RGB) video camera (CoolCam; SciMeasure,
Decatur, GA) or a Zeiss LSM-510 confocal microscope using
AIM 4.0 confocal software version 4.0 (Zeiss USA).
Preliminary experiments showed that the most effective
markers for lymphatics in mouse lungs were EGFP in Prox1-
EGFPetransgenic mice and VEGFR-3. The IHC ampliﬁed
Prox1-EGFP provided strong staining of lymphatics with little
or no background staining. Other conventional markers,
including LYVE-1 and podoplanin (gp38, T1a), were not as
useful for identifying lymphatics in mouse lung because of
expression in other cell types (Supplemental Figure S1, A and
B). Pulmonary blood vessels and tissue macrophages had
strong LYVE-1 immunoreactivity. Type 1 alveolar epithelial1579
Baluk et alcells had strong podoplanin immunoreactivity. Immunoreac-
tivity for neuropilin-2, a coreceptor forVEGFR-3,was stronger
in smaller- than in larger-diameter lymphatics (Supplemental
Figure S1C).Measurement of Lymphatics and BALT
The area density of lymphatics was measured in transverse
sections (200 mm thick) of the middle portion of the left lung.
The left lung, consisting of only one lobe, was used for mea-
surements because of its simpler structure compared with the
multiple-lobed right lung. To identify themain stem bronchus,
pulmonary artery, and pulmonary vein and provide a reference
framework for the lymphatics, we stained smoothmuscle cells
in the walls of airways and blood vessels for aSMA.19 For
morphometry, lung slices were stained for VEGFR-3 instead
of Prox1-EGFP, which was also expressed in cardiac muscle
cells of the proximal portion of the pulmonary vein and tended
to obscure the surrounding lymphatic vessels. Sections of the
midportion of the left lung were imaged with 10 (numerical
aperture, 0.5) objective lenses linked to a video camera and
digitizing tablet, and images were projected onto a color
monitor, as described previously.17 A rectangular survey box
with an area of 0.134mm2 consisting of 126 points arranged in
a simple square grid was superimposed on the projected image
of each of four regions: the main stem bronchus, pulmonary
vein, pulmonary artery, and lung parenchyma. The survey box
was positioned with one edge located along the transversely
cut edge of the bronchus, pulmonary artery, or pulmonary
vein, as identiﬁed by staining for aSMA so that the box con-
tained lymphatics associated onlywith that particular structure
(Figure 1). For the lung parenchyma, the survey box was
positionedover regions of the peripheral lung that hadminimal
aSMA immunoreactivity. The number of survey grid points
overlying tubular structures corresponding to lymphatics was
counted and expressed as a percentage of the total. Lungs from
at least ﬁve mice per group were counted for each condition.
For comparison, lymphatic area densities were also deter-
mined in whole mounts of tracheas stained for LYVE-1
immunoreactivity, with the survey box positioned over the
regions of mucosa overlying the cartilage rings.17 The diam-
eter of lymphatics was measured in sections stained for
VEGFR-3 or Prox1-EGFP. BALT was quantiﬁed by
measuring the area of regions of densely packed lymphoid
cells inH&E-stained sections of themidportion of the left lung
with the digitizing tablet at a magniﬁcation of 75 and was
expressed as a percentage of total lung area.Statistical Analysis
Values are presented as means  SEM, with at least ﬁve
mice per group unless otherwise indicated. The signiﬁcance
of differences between groups was assessed by analysis of
variance, followed by the Dunn-Bonferroni test for multiple
comparisons, with P < 0.05 considered signiﬁcant.1580Results
Distribution of Lymphatics in Normal Lung
The effect of M. pulmonis infection on lung lymphatics was
determined by ﬁrst obtaining baseline data for the distribution
of lymphatics in the lungs of pathogen-free mice. The
approach was to visualize lymphatics by immunoﬂuores-
cence staining for Prox1-EGFP or VEGFR-3 in thick slices of
the midportion of the left lung of mice (Figure 1). Smooth
muscle cells of airways and blood vessels in the slices were
similarly stained for aSMA to serve as reference structures.
Most lymphatics in lungs of pathogen-free mice were
located around large bronchi and major blood vessels near
the hilum (Figure 2A). Bronchi, pulmonary arteries, and
pulmonary veins could be distinguished from one another
by their characteristic arrangement of smooth muscle cells.
A common network of lymphatics surrounded pairs of
bronchi and pulmonary artery branches (Figure 2, A and B).
A seemingly separate lymphatic network surrounded pul-
monary veins (Figure 2, CeE). Lymphatics accompanied
airways and blood vessels into the lung parenchyma. The
lymphatic network extended further distally along the
branches of pulmonary veins than pulmonary arteries or
airways of comparable diameter (Figure 2C).
The number and distribution of lymphatics around bronchi,
pulmonary artery, pulmonary vein, and distal regions of the
lung under pathogen-free conditions provided a reference for
understanding changes that occurred after infection. Near the
lung hilum, lymphatics were comparably numerous around
the main stem bronchus, pulmonary artery, and pulmonary
vein (Figure 2F). However, lymphatics were <20% as
abundant in alveolar regions containing only small airways or
blood vessels of the distal lung parenchyma. In pathogen-free
lungs, the mean diameter of the largest lymphatics was
60 7mmat their entry at the hilumand38 7mmonmedium-
sized airways and vessels. The smallest lymphatics detected on
terminal branches of pulmonary veins (Figure 2, CeE) had a
diameter of 9  1 mm. Even near alveoli and visceral pleura,
lymphatics were typically associated with airways and blood
vessels (Figure 2, CeE). Few lymphaticswere locatedwithin or
beneath the visceral pleura (Figure 2, A, C, and E).Expansion of Lung Lymphatic Network after
M. pulmonis Infection
Lymphatics were conspicuously more abundant in lungs of
infected mice than in lungs of pathogen-free mice (Figures 2A
and 3A, respectively). Evaluation of lung sections at 0, 7, 14,
and 28 days after M. pulmonis infection revealed that the
lymphatic network expanded progressively during this period.
Most of the lymphangiogenesis occurred around major
bronchi, pulmonary arteries, and pulmonary veins (Figure 3,
AeC). From 7 days of infection onward, lymphatics around
bronchi and pulmonary vessels had abundant endothelial
sprouts; by comparison, lymphatics in pathogen-free lungsajp.amjpathol.org - The American Journal of Pathology
Figure 2 Number and distribution of lymphatics in lung of pathogen-free mice. Lymphatics are stained for Prox1-EGFP immunoreactivity (green). Smooth
muscle cells stained foraSMA (red) delineate the wall of airways and blood vessels.A: Overview of the distribution of lymphatics in the midportion of the left lung.
Lymphatics encirclemajor bronchi and blood vessels and followbranches toward the lungperimeter. No lymphatics are present in the visceral pleura.Boxed regions
in A are shown enlarged in B (A,middle box), C (A, top box), and E (A, bottom box) B: Smooth surfaced lymphatics on bronchus (Br) near the hilum. Typical of
bronchi, bands of smooth muscle cells (aSMA, red) are oriented perpendicular to the airway axis. Also visible are small branches of the pulmonary artery (PA;
arrows) and pulmonary vein (PV; arrowhead). C: Smooth surfaced lymphatics on a small branch of PV (arrowhead). Small branches of PA that lack lymphatics are
also visible (arrows). D: Enlargement of boxed region in C showing the relationship of lymphatics (arrowhead) to smooth muscle of small PV (arrows). E:
Lymphatics in distal lung on small branches of PV. F: Relative abundance of lymphatics aroundmajor bronchi, branches of PA and vein, and distal lung parenchyma
in cross section (200mm thick) of themid region of the left lung. Dots show themean area density of lymphatics marked by VEGFR-3 staining in eachmouse. Values
for Br and pulmonary vessels are not signiﬁcantly different from one another. *P< 0.05 between Br and pulmonary vessels (NZ 13 to 15 mice per group). Scale
bars: 200 mm (AeC and E); 50 mm (D).
Lymphangiogenesis in Lung Inﬂammationhad a smooth surface (Figure 3, D and E). Regions around
large bronchi and pulmonary vessels, where lymphatics were
most abundant, were sharply demarcated from regions of type
1 alveolar epithelial cells in lung alveoli (Figure 3, F and G).The American Journal of Pathology - ajp.amjpathol.orgThe increase in lymphatics was approximately equivalent
around large bronchi, pulmonary arteries, and pulmonary
veins. Overall values calculated from average values for the
three regions were used to determine the time course of1581
Figure 3 Expansion of lymphatic network in mouse lung after M. pulmonis infection. A: Overview of lymphatics in the midportion of the left lung near the hilum
after infection for 28 days. Abundant lymphatics (Prox1-EGFP, green) found around major bronchus (Br), pulmonary artery (PA), and pulmonary vein (PV), shown by
smoothmuscle (aSMA, red) in the wall, but few lymphatics in the distal lung. Boxed regions are shown enlarged in C (A, lower box) and Supplemental Figure S2A (A,
upper box). Comparison of few small lymphatics (Prox1-EGFP, green) on a pulmonary vein branch in lung of pathogen-freemouse (B) with abundant larger lymphatics
on a pulmonary vein after infection for 28 days (C). Comparison of smooth surfaced lymphatic in lung of pathogen-free mouse (D) and lymphatics with sprouts
(arrowheads) in lung after infection for 7 days (E). Lymphatics shownby VEGFR-3 immunoreactivity (green). Comparison of few lymphatics (Prox1-EGFP, green) in the
narrow space around Br and PA of lung of pathogen-free mouse (F) with abundant lymphatics in cuff of lymphoid tissue around pulmonary artery and bronchus after
infection for 28 days (G). Region of lymphatics in lymphoid tissue is sharply demarcated from surrounding lung parenchymawith type 1 alveolar epithelial cells shown
by aquaporin-5 immunoreactivity (red). H: Time course of expansion of lymphatic network in left lung from pathogen-free state (0) to 7, 14, and 28 days after
infection. Each red dot represents the average value for lymphatics near bronchi, pulmonary arteries, and pulmonary veins in each mouse at one time point. Mean
values after infection are signiﬁcantly different from baseline (*P< 0.05). Blue dots are corresponding values for lung parenchyma, which are signiﬁcantly less than
red values but not different fromone another (NZ4 to15mice per group). I: CellswithVEGF-C immunoreactivity (red, arrows) near lymphatics (Prox1-EGFP, green) in
BALT around PA after infection for 7 days. J: Higher-magniﬁcation view of I showing the distribution of cells in which staining for VEGF-C (red) and CD45 (green) are
colocalized (orange, arrows). Scale bars: 200 mm (A, F, and G); 50 mm (BeE and I); 20 mm (J). Br, bronchi; PA, pulmonary artery.
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Lymphangiogenesis in Lung Inﬂammationlymphatic network expansion (Figure 3H). These data
revealed that the lymphatic network expanded threefold
during the ﬁrst 7 days after infection and continued to in-
crease to approximately sixfold at 28 days (Figure 3H). In
sharp contrast to these regions, lymphatics in the lung pa-
renchyma did not increase after infection (Figure 3H). Few
sprouts were found on lymphatics on distal regions of lung
parenchyma, including small bronchi, blood vessels
(Supplemental Figure S2A), and visceral pleura.
Further changes in lung lymphatics after infection included
stronger CCL21 immunoreactivity in lymphatic endothelial
cells (Supplemental Figure S2, BeG). CCL21 was wide-
spread in lung lymphatics after infection, was relatively
speciﬁc to lymphatic endothelial cells, and contrasted with
weak staining in pathogen-free lungs, where it was restricted
to the perinuclear region of lymphatic endothelial cells
(Supplemental Figure S2, BeG). No change was detected in
the intensity of VEGFR-3 or Prox1-EGFP immunoreactivity
in lymphatics after infection. LYVE-1 and podoplanin anti-
bodies proved to be unsuitable for staining lymphatics in the
lung because they also labeled other cell types. Immunore-
activity for neuropilin-2, a coreceptor for VEGFR-3, was not
uniformly strong on lymphatics of all sizes to be used as a
reliable marker (Supplemental Figure S1, AeC).
In search of potential drivers of lymphatic growth and
remodeling after infection, we examined the distribution
and abundance of cells that express the potent lym-
phangiogenic factor, VEGF-C. We found that VEGF-
Ceimmunoreactive cells were located preferentially in
BALT around large bronchi and pulmonary vessels
(Figure 3, I and J). VEGF-Cepositive cells were numerous
in regions of the expanded lymphatic network in BALT,
but were sparse or absent in the adjacent lung parenchyma
(Figure 3I). Staining for CD45 identiﬁed the VEGF-Ce
immunoreactive cells as a subpopulation of mononuclear
leukocytes (Figure 3J).
Preferential Growth of Lymphatics in BALT after
M. pulmonis Infection
Distribution of Inﬂammation after Infection
The progression of lung inﬂammation after M. pulmonis
infection was examined in H&E-stained sections at 0, 7, 14,
and 28 days after infection. Two concurrent processes were
evident: formation of cuffs of lymphoid tissue around
inﬂamed airways and major blood vessels and accumula-
tions of inﬂammatory cells in alveoli typical of lobar
pneumonia (Figure 4A). Peribronchial and perivascular ac-
cumulations of lymphoid tissue ﬁt with published de-
scriptions of BALT.29e33 Cell inﬁltration increased with
duration of infection, and at 28 days, some regions of lung
parenchyma were consolidated by inﬂammatory cell inﬁl-
trate (Figure 4, A and B).
The amount of BALT increased from none in pathogen-
free lungs to an average of >15% of the total lung area at
28 days of infection, but it varied among mice at each timeThe American Journal of Pathology - ajp.amjpathol.orgpoint and at 28 days ranged from almost none to 30%
(Figure 4C). The mean wet weight of the left lung
increased 2.5-fold during this period (Figure 4D). Typical
of BALT, the lymphoid aggregates contained HEVs, sites
of lymphocyte homing identiﬁed by the presence of pe-
ripheral node addressin marked by MECA-79 antibody
(Figure 4E). In addition, the airway epithelium overlying
BALT contained M cells, which are sites specialized
for antigen entry identiﬁed by U. europaeus lectin binding
(Figure 4F).31,34 Lymphatics were most abundant in re-
gions of loosely packed T cells around, but not inside,
B-cell follicles of BALT (Figure 4, GeI).
Time Course of Sprouting Lymphangiogenesis in BALT
The temporal relationship between lymphocyte inﬂux,
BALT formation, and lymphangiogenesis was examined
during early stages of infection. Pathogen-free lungs had
few B or T cells (Supplemental Figure S3, AeC). At 3
days of infection, the number of T cells was conspicuously
increased throughout the lung parenchyma. This was the
earliest time point when clusters of lymphocytes, espe-
cially T cells, were found near lymphatics (Supplemental
Figure S3, DeF). At 3 days, lymphatics appeared
normal, but at 5 days, sprouts were present on lymphatics,
and B-cell follicles were evident around airways and large
vessels (Supplemental Figure S3G). T and B cells were
present in the lumen of some lymphatics (Supplemental
Figure S3, H and I).
Diverse Inﬂammatory Cells in BALT and Lung Parenchyma
after Infection
Macrophages, dendritic cells, and neutrophils were abun-
dant along T and B cells in BALT. Macrophages and den-
dritic cells, identiﬁed by immunoreactivity for Aif1/Iba1,
were sufﬁciently numerous to delineate the margins of
BALT (Figure 4J). Neutrophils, identiﬁed by S100A8
immunoreactivity, were scattered in BALT but were much
more abundant in the airway lumen (Figure 4K). These
inﬂammatory cells were also abundant in the lung paren-
chyma of infected mice (Figure 4, L and M). Lymphatics in
BALT and distal branches of pulmonary veins in the lung
parenchyma coursed through macrophage- and neutrophil-
rich regions (Figure 4, L and M), but only the lymphatic
network in BALT underwent conspicuous expansion.
Contribution of VEGFR-3 and VEGFR-2 Signaling to
Lymphangiogenesis in Lung
Effect of Blocking VEGFR-3 and/or VEGFR-2 on Lung
Lymphatics
To determine the contribution of VEGFR-3 and/or VEGFR-
2 signaling to the expansion of the lung lymphatic network
after infection, we treated mice with function-blocking an-
tibodies to VEGFR-3 and/or VEGFR-2 from the onset of
infection, and measured the abundance of lymphatics at 14
days. Lymphatics in both the lung and the trachea were1583
Figure 4 Lymphatics in BALT. A: Montage of H&E-stained sections of mouse left lung at 0, 7, 14, and 28 days after M. pulmonis infection. At 7 days,
BALT (intense purple) is greatest in the hilum. The overall amount of BALT increases during the infection. By 28 days, the entire lung consists of regions
of BALT surrounded by consolidated lung parenchyma typical of lobar pneumonia (less intense purple areas). B: After 28 days of infection, the main
bronchus (Br) and pulmonary artery (PA) are surrounded by BALT, which has a sharp border with the lung parenchyma. The pulmonary vein (PV) has a
separate cuff of BALT. Lymphoid follicles (arrows). C: Time course of increase in amount of BALT expressed as percentage of total area of H&E-stained
sections of mouse left lung at 0, 7, 14, and 28 days after infection. Infected values are signiﬁcantly greater than pathogen free and increase with
infection duration (*P < 0.05; N  5 mice per group). D: Time course of increase in left lung wet weight, expressed relative to the control (0 days)
weight, at 0, 7, 14, and 28 days after infection. Infected values are signiﬁcantly different from pathogen free; values at 28 days are different from values
at 7 and 14 days (*P < 0.05; N  13 mice per group). EeM: A 28-day infection. E: MECA-79 immunoreactivity (red) marks HEVs (arrowheads) in BALT
around bronchus (Br) and pulmonary vein (PA). Blood vessels marked by PECAM-1 immunoreactivity (green). F: M cells stained by U. europaeus lectin
(red) in the bronchial epithelium after 28 days of infection. Epithelial cells (pan-keratin, blue). Lymphatics (Prox1-EGFP, green, arrow). G: B-cell follicles
(B220, red) and lymphatics (Prox1-EGFP, green) in BALT after infection for 28 days. H: Enlargement of B-cell follicle in G (arrow). B cells (B220, red) are
more abundant than T cells (CD3e, cyan). Lymphatics (Prox1-EGFP, green, arrow) in the T-cell zone but not in the B-cell zone. I: Enlargement of
perifollicular lymphatic (Prox1-EGFP, green) in H (arrow), showing B cells (B220, red) and T cells (CD3e, cyan) in the lumen. J: Macrophages and
dendritic cells (Aif1/Iba1, red) surround lymphatics (Prox1-EGFP, green) and outline the border of BALT around a Br. K: Neutrophils (S100A8, red)
scattered near lymphatics (Prox1-EGFP, green) in BALT around a Br and found in clumps (arrow) in the airway lumen. L: Lung parenchyma near pleura
showing abundant neutrophils (S100A8, red) and scattered lymphatics (Prox1-EGFP, green). M: Higher magniﬁcation of region in L showing neutrophils
(S100A8, cyan) and macrophages and dendritic cells (Aif1/Iba1, red) near lymphatics (Prox1-EGFP, green). Scale bars: 1000 mm (A); 400 mm (B and G);
200 mm (E and JeL); 50 mm (F, H, and M); 20 mm (I).
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Lymphangiogenesis in Lung Inﬂammationassessed to build a bridge to our previous work on lym-
phangiogenesis in the trachea after M. pulmonis infection.17
The earlier study revealed that inhibition of VEGFR-3 alone
completely inhibited lymphangiogenesis in the trachea after
infection.17 We reasoned that if a different result were ob-
tained in the lung, the change in the trachea would enable us
to bridge to the earlier ﬁndings and know whether the new
experiment matched the previous one. Lymphatics were
visualized in the trachea by staining for LYVE-1 but were
visualized in the lung by VEGFR-3 immunoreactivity to
avoid confusion by lung blood vessels with LYVE-1
immunoreactivity.
As a reference, tracheal lymphatics increased 12-fold
over the pathogen-free value during infection for 14 days in
mice that received control rat IgG (Supplemental Figure S4,
A and B). The increase was 40% less in mice treated with
the VEGFR-2eblocking antibody DC101 (Supplemental
Figure S4C) and 98% less in mice treated with the
VEGFR-3eblocking antibody mF4-31C1 (Supplemental
Figure S4, D and F). Tracheal lymphatics in infected
mice receiving the antieVEGFR-2 and antieVEGFR-3
antibodies together were similar to those receiving anti-
eVEGFR-3 alone (Supplemental Figure S4, E and F). Both
resembled the lymphatics in pathogen-free controls.
The results were similar, but not identical, in the lung
(Figure 5, AeF). The infected group that received control IgG
had a fourfold increase in lung lymphatics over the pathogen-
free baseline (Figure 5, A and B). The apparently greater in-
crease in the tracheawasmore a reﬂection of differences in the
pathogen-free baseline values in the trachea and lung than
amount of increase after infection. Lung lymphatics were
68% less numerous in mice treated with VEGFR-2eblocking
antibody (Figure 5C), 83% less in mice treated with VEGFR-
3eblocking antibody (Figure 5D), and 99% less in mice
treated with both antibodies together (Figure 5, E and F).
None of the treatments had a measurable effect on the abun-
dance of lymphatics in the lung parenchyma (Figure 5F).
Values for trachea and lung in the same mice had a signiﬁcant
correlation by linear regression analysis, with a coefﬁcient of
determination R2 of 0.54 (P < 0.05).
Effect of Blocking VEGFR-3 and/or VEGFR-2 on BALT and
Lymph Nodes
The overall effect on lung inﬂammation of blocking
VEGFR-3 and/or VEGFR-2 was assessed by examining the
amount of BALT (Figure 5G) and bronchial lymph node
hypertrophy. Measurements of BALT in H&E-stained sec-
tions of lungs gave similar values in all infected mice,
regardless of antibody treatment (Figure 5H), and all
infected groups were signiﬁcantly greater than the amount
in pathogen-free mice (Figure 5H). The amount of BALT in
these treatment groups was similar to that found at 14 days
in the earlier time course study (Figure 4C).
During the 14-day infection, bronchial lymph nodes
increased sixfold in weight. Blocking VEGFR-2 andVEGFR-3
together reduced the weight by 50%, but blocking eitherThe American Journal of Pathology - ajp.amjpathol.orgVEGFR-2 or VEGFR-3 alone had no signiﬁcant effect on
lymph node weight (Figure 5I).
After having learned that blocking VEGFR-2 and/or
VEGFR-3 did not change the amount of BALT, we asked if
the blood vasculature of BALT was affected, to test the
possibility that these inhibitors prevented angiogenesis that
normally occurs as lymphoid tissue expands. Studies of
BALT vasculature revealed that nonfollicular regions of
BALT contained abundant blood capillaries and HEVs. The
vessel types were readily distinguished because HEVs were
much larger than capillaries (Figure 5J). Lymphoid follicles
had fewer blood capillaries and no HEVs. When VEGFR-2
and VEGFR-3 were inhibited together throughout the 14-
day infection, capillaries in BALT were less than half as
numerous, but HEVs seemed unaffected (Figure 5K).
Lack of Lymphatic Sprouting after Overexpression of
VEGF-A
To explore evidence for the involvement of VEGFR-2 in
sprouting and growth of lung lymphatics after M. pulmonis
infection, we asked whether VEGF-A, a potent ligand for
VEGFR-2, made a contribution. To address this question,
we used Clara cell secretory protein (CCSP)eVEGF-Ae
transgenicmice as amodel inwhichVEGF-Aexpression, under
the control of the CCSP promoter, triggers abundant angio-
genesis in the trachea and lung when activated by doxycycline
administration.28 Sections of lungs of CCSPeVEGF-A mice
taking doxycycline for 14 days had usually abundant blood
vessels in the bronchial mucosa, but no expansion or sprouting
of neighboring lymphatics, compared with CCSPeVEGF-A
mice taking water (Supplemental Figure S4, G and H).
Persistence of Lung Lymphatics after Resolution of
Infection
To build on our previous observation that newly formed lym-
phatics persisted in tracheas long after M. pulmonis infection
was eliminated by antibiotic treatment,17 we sought to deter-
mine whether the same occurred in the lung. Mice infected for
14 days were then treated for a further 14 days with vehicle or
with oxytetracycline to eliminate the infection. The experiment
had a clear outcome: BALT was extensive in H&E-stained
sections of untreated lung, but was sparse or absent in lungs of
infected mice treated with the antibiotic (Figure 6, AeD and I).
However, in the same mice, the abundance of lymphatics
around major bronchi and pulmonary vessels was not signiﬁ-
cantly reduced by oxytetracycline (Figure 6, EeH and J).
Treatment with the antibiotic had a similar effect on bronchial
lymph nodes as on BALT: lymph node weight was reduced
almost to pathogen-free levels (Figure 6K).
Discussion
We sought to determine the number and distribution of lym-
phatics in the lung of mice, how lung lymphatics change after1585
Figure 5 Effect of treatment of mice with control IgG or function-blocking antibodies to VEGFR-2 (DC101) and/or VEGFR-3 (mF4-31C1) on lymphangiogenesis
and angiogenesis in lung during M. pulmonis infection for 14 days. Pathogen-free controls had no treatment. AeE: Lymphatics around bronchus (Br), pulmonary
artery (PA), or pulmonary vein (PV) near hilum. Lung sections stained for VEGFR-3 (red) and aSMA (green). A: Sparse lymphatics in pathogen-free mouse. B:
Abundant lymphatics in infected mouse treated with control IgG. C: Abundant lymphatics in infected mouse treated with antieVEGFR-2. D: Sparse lymphatics in
infected mouse treated with antieVEGFR-3. E: Sparse lymphatics in infected mouse treated with antieVEGFR-2 and antieVEGFR-3. F: Relative abundance of
lymphatics in lung of pathogen-free mice and infected mice treated with VEGFR blocking antibodies. Red dots represent average value for lymphatics around
bronchus, pulmonary artery, and pulmonary vein in eachmouse. Blue dots represent corresponding values for lung parenchyma. *P< 0.05 compared to baseline; yP
< 0.05 compared to infected mice treated with control IgG. No signiﬁcant differences among lung parenchyma groups (NZ 5 to 11 mice per group). G: H&E-
stained section of left lung of infected mouse treated with antieVEGFR-2 and antieVEGFR-3 showing BALT with lymphoid follicle (arrow) around Br and PA. H:
Amount of BALT, expressed as percentage of total lung area, measured in H&E-stained lung sections of pathogen-free mice and infected mice treated with VEGFR
blocking antibodies. BALT was not present in lungs of pathogen-free mice. Signiﬁcantly different from pathogen-free group (*P < 0.05), but no signiﬁcant
differencewas found among the treatment groups (NZ 5 to 8mice per group). I:Bronchial lymphnodewetweight in pathogen-freemice and infectedmice treated
with VEGFR blocking antibodies. Signiﬁcantly different from pathogen-free group (*P< 0.05) or other groups of infected mice (yP< 0.05) (NZ 5 to 11 mice per
group). J and K: Blood vessels (PECAM-1, green) and leukocytes (CD45, red) in BALT near bronchus. Infected mouse treated with control IgG. J: BALT contains
abundant leukocytes, blood capillaries (arrowheads), and HEVs (arrow). Infected mouse treated with antieVEGFR-2 and antieVEGFR-3. K: BALT has fewer blood
capillaries (arrowhead), but larger blood vessels (HEVs, arrow) are still present.
Baluk et al
1586 ajp.amjpathol.org - The American Journal of Pathology
Figure 6 Reversibility of BALT formation, but not lymphangiogenesis, after M. pulmonis infection. H&E-stained sections of mouse left lung comparing
pathogen-free state (A), infection for 14 days (B), infection for 28 days with vehicle treatment during ﬁnal 14 days (C), and infection for 28 days with
antibiotic (oxytetracycline) during ﬁnal 14 days (D). BALT is abundant around bronchus (Br) and pulmonary artery (PA) in infected mice, except in antibiotic-
treated group. Confocal microscopic images of lungs under same conditions as in A to D comparing the sparse lymphatics (VEGFR-3, red) around major Br and
PA in pathogen-free lung (E) with the abundant lymphatics after infection, where lymphatics are similarly numerous in all infected groups (FeH). I: Per-
centage of lung sectional area occupied by BALT under same conditions as in A to D. J: Area density of lung lymphatics shown by VEGFR-3 immunoreactivity
around major bronchi and pulmonary vessels under same conditions as in A to D. Values are greater after infection and not reduced by antibiotic (Oxy) during
ﬁnal 14 days of 28-day infection. K: Bronchial lymph node weight under same conditions as in A to D. NZ 4 to 5 mice per group. *P < 0.05 from pathogen-
free group, yP < 0.05 from 28-day infection with vehicle (Veh) treatment.
Lymphangiogenesis in Lung InﬂammationM. pulmonis infection, the contribution of VEGFR-2 and
VEGFR-3 signaling to the lymphatic growth, and the
reversibility by treatment of the infection. Lungs were found
to have a well-developed and regionally highly specialized
lymphatic network. On infection, lymphangiogenesis was
conspicuous but was restricted to regions of lymphoid tissue
that formed around the major bronchi and blood vessels.
Lymphatics in the distal lung parenchymawere little changed,
even where inﬂammatory cell inﬂux was extensive. The
growth of new lymphatics in BALT was found to require
signaling of both VEGFR-2 and VEGFR-3, but blocking
these receptors did not prevent the formation of BALT.BALT
resolved when the infection was treated with the antibiotic
oxytetracycline, but not with the new lymphatics.The American Journal of Pathology - ajp.amjpathol.orgRelation of Murine M. pulmonis Infection to Human
Pulmonary Disease
Mycoplasma pulmonis infection has multiple attributes for
studies of sustained lung inﬂammation because these natural
murine pathogens have co-evolved with their host to reach a
balance between infection of the respiratory tract and elimi-
nation by host immune responses. Compared with transient
pulmonary infections or irritants, the inﬂammatory stimulus
providedbyM.pulmonis is sustained and consequently leads to
progressive pathological characteristics.29Themousemodel of
lymphangiogenesis in sustained lung inﬂammation reported
herein might also be relevant to human pulmonary disease.
BALT develops in several human lung diseases, including1587
Baluk et alCOPD, idiopathic pulmonary ﬁbrosis, hypersensitivity pneu-
monitis, and rheumatoid arthritis, where it may result from
opportunistic secondary lung infections.35,36 However, we are
aware of only one clinical report that mentions the presence of
lymphatics in BALT of lungs.5 The authors of that study
concluded that BALT and associated lymphatics contributed to
aggravated inﬂammation in COPD.
Comparison of Lung Lymphatics in Pathogen-Free and
Infected Mice
Most lymphatics in lungs of pathogen-free mice, as in other
species, accompanied the major bronchi and blood vessels,
especially pulmonary veins. Fewer lymphatics were located
in the lung parenchyma. These ﬁndings are in broad agree-
ment with a recent study of lung lymphatics in pathogen-free
mice.19 Compared with larger organisms, such as rat,37
sheep,38 or human,39 a notable difference in the architec-
ture of lymphatics in mouse lung was their almost complete
absence in the visceral pleura.
From the results of previous studies of trachea in
M. pulmoniseinfected mice,17,18,40e42 it seemed likely that
lymphangiogenesiswould alsooccur in the lung after infection,
but we did not know how,when, or where it would happen. An
unexpected ﬁnding in the current study was that most of the
lymphangiogenesis in lungs after infection occurred in regions
of BALT around the major airways and blood vessels. In this
respect, our ﬁnding differed from that of a report in which
no signiﬁcant changes were found in lymphatics in lung
inﬂammation induced by administration of house dust mite
allergen.19 The reason for the difference is not clear but prob-
ably involves the nature, severity, and duration of the inﬂam-
matory response under the two conditions.
Time Course of Changes in Lymphatics
In this study, much of the lymphatic growth in the lung
occurred within the ﬁrst 7 days after infection, but lym-
phangiogenesis continued for at least 28 days. The onset of
lymphatic growth was more rapid in the lung than in the tra-
chea, where lymphatic sprouting began around 7 days and
was not obvious until 14 days. The slower lymphangiogenesis
in the trachea could reﬂect the spread of infection from the
lung tomore proximal airways. At any rate, for this reason,we
used the 14-day time point to compare the effects of VEGFR-
2/VEGFR-3eblocking antibodies in lungs and trachea.
Of the markers of lymphatic phenotype examined,
CCL21 was the only one that was clearly greater in infected
lungs than in pathogen-free lungs. CCL21 immunoreactivity
was increased not only in the newly formed lymphatics but
also in the extracellular matrix. These ﬁndings are consistent
with recent reports of increased CCL21 secretion by in-
ﬂammatory stimuli, thereby facilitating mobilization and
trafﬁcking of dendritic cells and lymphocytes into activated
lymphatics.43e46 Increased CCL21 staining has also been
reported on lung lymphatics in patients with COPD.61588Relationship of Changes in Lymphatics to other
Inﬂammatory Changes
The present study showed that changes in mouse lung
lymphatics after infection happened more or less in parallel
with peribronchial and perivascular lymphoid cufﬁng by
BALT and development of pneumonia. Both processes were
recognized many years ago in mouse lungs after M. pul-
monis infection,29 but have not previously been examined in
the context of lung lymphatics. Lymphangiogenesis was
closely associated with the formation of BALT but not with
the development of pneumonia.
Although numerous studies conﬁrm that experimental
bacterial or viral infection can induce BALT in mouse
lungs,33,47,48 lymphatics in BALT have received relatively
little attention.35 The present study showed that the peri-
bronchial and perivascular cuffs in mouse lungs infected with
M. pulmonis had all of the features characteristic of BALT,
including the presence of HEVs,32,49 epithelial M cells,31,34
and B-cell follicles surrounded by T-cell zones.30,32
Our ﬁnding that lymphangiogenesis in the lung was
largely restricted to BALT after M. pulmonis infection has
several implications. First, it suggests that functions of the
newly formed lymphatics relate more to BALT than to
general ﬂuid balance or cell trafﬁcking in other regions of
the lung. For immune cells that enter the lung via HEVs in
BALT, the newly formed lymphatics are likely to be an exit
route.11 In this context, the location of lymphatics in pe-
ripheral regions of BALT some distance from the airway
epithelium indicates that antigens and antigen-presenting
cells traverse the thickness of BALT to reach lymphatics.
Our observation of leukocytes in the lumen of lymphatics
in BALT suggests that the newly formed lymphatics could
be functional in terms of immune cell trafﬁcking. The
ﬁnding of VEGF-C and lymphangiogenesis in BALT
suggests that local factors drive lymphatic growth. B cells
have been claimed to drive lymphangiogenesis in inﬂamed
lymph nodes.25 In the present study, VEGF-Cecontaining
cells and the newly formed lymphatics were located in T-
cell regions of BALT, but not in B-cell follicles. The
involvement of T or B cells is suggested by evidence that
lymphangiogenesis does not occur after M. pulmonis
infection in immunodeﬁcient recombination-activating
geneedeﬁcient mice or B-celledeﬁcient mice.40
There is no consensus on whether BALT is beneﬁcial or
detrimental to the host after M. pulmonis infection. Like
other features of sustained inﬂammation, BALT is probably
both good and bad for different aspects of disease. Because
BALT changes normal lung structure and could affect gas
exchange, it would appear to be bad for the lung. However,
because BALT could help conﬁne the disease to the airways
and lungs and prevent dissemination to distant sites, it
would be beneﬁcial for the host overall. In recombination-
activating gene mice, severe combined immunodeﬁcient
mice, B-celledeﬁcient mice, and mice treated with the
immunosuppressant cyclophosphamide, BALT does notajp.amjpathol.org - The American Journal of Pathology
Lymphangiogenesis in Lung Inﬂammationdevelop after M. pulmonis infection and the lungs are rela-
tively normal. However, the bacteria disseminate throughout
the body and infect the pericardium, liver, spleen, and even
joints, where severe arthritis can develop.40,50e52Dependency of Lung Lymphatic Growth on VEGFR-3
and VEGFR-2 Signaling
Our studies with blocking antibodies showed that VEGFR-3
signaling was the main, but not the only, driving force for
lymphangiogenesis in lungs after M. pulmonis infection.
The ﬁnding that VEGFR-3 signaling is dominant is
consistent with the presence of VEGF-C in inﬂammatory
cells in BALT and with evidence for lymphatic growth in
other organs.20 However, VEGFR-2 signaling also had a
role in the lung. The involvement of both VEGFR-3 and
VEGFR-2 in lymphangiogenesis has been shown in
skin,23,53e55 lymph nodes,25,56 cornea,57 and tumors.26 In
all locations, VEGFR-3 has the stronger effect. VEGF-A is
reported to drive lymphatic growth through VEGFR-2 in
embryonic mouse lungs,58 but, to our knowledge, this has
not been examined in adult lungs. The present studies of
VEGF-A overexpression in CC10eVEGF-A mice detected
no lymphangiogenesis, despite the robust angiogenesis. The
relative lack of changes in lymphatics in distal regions of
lung parenchyma, despite the presence of abundant in-
ﬂammatory cells, indicates that the microenvironmental
conditions necessary for lymphangiogenesis differ in BALT
from other regions of the lung.
How VEGFR-2 signaling contributes to lymphangio-
genesis is not well understood. Several direct and indirect
mechanisms have been proposed. Because both VEGFR-3
and VEGFR-2 are expressed on lymphatic endothelial
cells,20 it has been proposed that VEGF-A and VEGF-C
stimulate their respective receptors to promote different
aspects of lymphangiogenesis, radial enlargement, and
lymphatic sprouting.55 VEGF-A, and even more potently
VEGF-C, can promote the formation of VEGFR-2/
VEGFR-3 heterodimers that can be activated by either
growth factor.59 Antibodies that prevent VEGFR-3/
VEGFR-2 heterodimer formation can inhibit both angio-
genesis and lymphangiogenesis.60 Signaling through het-
erodimers can also be inﬂuenced by regulatory molecules,
such as Bmx kinase, that modulate downstream signaling
pathways.61
VEGF-A can recruit macrophages, promote angiogenesis,
and induce plasma extravasation. Because some macro-
phages secrete VEGF-C, inhibiting VEGFR-2 signaling
could reduce lymphangiogenesis by suppressing macro-
phage inﬂux.20,57 Inhibition of VEGFR-2 signaling could
also inhibit lymphangiogenesis by reducing plasma leakage
and thereby reduce mediators from extravasated plasma that
contribute to macrophage or immune cell recruitment,
activation of extracellular proteases, or other processes that
produce lymphangiogenic factors.The American Journal of Pathology - ajp.amjpathol.orgIssues Still to be Resolved about Lung Lymphatics
Further studies will be needed to address the complexities of
VEGFR-3/VEGFR-2 interactions in lymphangiogenesis.
Experiments using CCSPeVEGF-Aetransgenic mice
showed that VEGF-A overexpression in respiratory tract
epithelial cells produced angiogenesis without lymphangio-
genesis in the lungs. These results are consistent with earlier
ﬁndings in the trachea,28 but could appear inconsistent with
evidence of the involvement of VEGFR-2 signaling in the
growth of lymphatics in the lung afterM. pulmonis infection.
A possible explanation could be that the human VEGF-A
(VEGF165), and not mouse VEGF-A (VEGF164), is over-
expressed in this transgenic mouse62 and could inﬂuence the
ability to promote VEGFR-3/VEGFR-2 heterodimer forma-
tion and downstream signaling in the host mouse.
Among the other issues requiring further work is the
identity of cells that produce VEGF-C and/or VEGF-D in
inﬂamed tissues. Additional work is also needed to determine
the functionality of new lymphatics that grow in the lung in
sustained inﬂammation. Although many technical challenges
need to be overcome, there is hope that live-imaging tech-
nologies will provide insights into their function.12,46,63,64
Although BALT was required for the growth of new
lymphatic vessels, the converse appears not to be true.
Prevention of lymphangiogenesis by treatment with anti-
bodies that blocked both VEGFR-3 and VEGFR-2 did not
prevent BALT development. However, in agreement with
previous studies of inﬂamed skin,25 the antibody combina-
tion did reduce the enlargement of the draining lymph node
that occurs in M. pulmonis infection. The mechanism of
suppression of lymph node growth is not known, but could
involve the reduced cell trafﬁcking and ﬂuid drainage from
the inﬂamed organ to the lymph node and reduced angio-
genesis and lymphangiogenesis in the lymph node.
The ﬁnding of lymphangiogenesis occurringmainly within
BALT in infected lungs resembles features of Hashimoto’s
thyroiditis in humans and in transgenic mouse models65,66
and human renal transplant rejection.67,68 Sustained im-
mune cell activity and defective lymphatic drainage are
thought to trigger the formation of ectopic germinal centers
and lymphangiogenesis in such chronic inﬂammatory con-
ditions.69 New patterns of lymph ﬂow are established that
result in a self-perpetuating feedback loop that sustains the
local immune response. In this way, lymphoid cells and
lymphatics are mutually interdependent. Persistence of new
lung lymphatics after the infection resolves could accelerate
or amplify responses to subsequent infections.
Summary
In this study, we sought to learn how lung lymphatics change
in sustained inﬂammation and to understand themechanism of
the changes. After M. pulmonis infection in C57BL/6 mice,
BALT formed around major bronchi and pulmonary blood
vessels. AsBALTaccumulated, lymphatics grewby sprouting1589
Baluk et allymphangiogenesis preferentially within T-cell regions that
containedVEGF-Ceproducing CD45-positive cells. The new
lymphatics had higher than normal expression of CCL21.
Little lymphatic growth occurred in distal regions of lung
parenchyma, despite the presence of abundant inﬂammatory
cells in regions of pneumonia. Experiments using function-
blocking antibodies revealed that signaling through the two
VEGF-Cedriven receptors, VEGFR-3 and VEGFR-2,
accounted for 99% of the lymphangiogenesis in the lung
under these conditions. The new lymphatics were remarkably
persistent after resolution of the infection by treatmentwith the
antibiotic oxytetracycline. The lack of regression of the new
lung lymphatics, despite regression of theBALT inwhich they
grew, could exaggerate responses to subsequent infections.
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